Summary
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Age 18 or older * Newly diagnosed stage III or IV CC or EC * Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis. * Told by their physician that their disease is stable. * Patients must have informed consent form (ICF) signed for the study. Exclusion Criteria: * Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. * Previously participated in or participating in a clinical trial. * Patients who received another line of therapy after initial therapy. * Unable or unwilling to provide informed consent. * Not fluent in local language. * Indicates or exhibits hearing difficulties, which would make a conversation challenging.